Seminars in Oncology
Volume 31, Issue 1 , Pages 37-46 , February 2004

Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion

  • Larry W Kwak

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Larry W. Kwak, MD, PhD, Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    • Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    • ,
  • Sattva S Neelapu

      Affiliations

    • Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    • ,
  • Michael R Bishop

      Affiliations

    • Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

References 

  1. Brichard V, Van Pel A, Wolfel T, et al.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993;178:489–495
  2. Disis ML, Calenoff E, McLaughlin G, et al.  Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 1994;54:16–20
  3. Gissmann L, Jochmus I, Nindl I, et al.  Immune response to genital papillomavirus infections in women. Prospects for the development of a vaccine against cervical cancer. Ann NY Acad Sci. 1993;690:80–85
  4. Jerome KR, Barnd DL, Bendt KM, et al.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 1991;51:2908–2916
  5. Kawakami Y, Eliyahu S, Delgado CH, et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994;91:3515–3519
  6. Livingston PO, Wong GY, Adluri S, et al.  Improved survival in AJCC stage III melanoma patients with GM2 antibodies (A randomized trial of adjuvant vaccination with GM2 ganglioslide). J Clin Oncol. 1994;12:1036–1044
  7. Miller RA, Maloney DG, Warnke R, et al.  Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517–522
  8. Stevenson GT, Stevenson FK. Antibody to molecularly defined antigen confined to a tumor cell surface. Nature. 1975;254:714–716
  9. Stevenson GT, Elliott EV, Stevenson FK. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes (A therapeutic target). Fed Proc. 1977;36:2268–2271
  10. Bridges SH. Participation of the humoral immune system in the myeloma specific transplantation resistance. J Immunol. 1978;121:479–483
  11. Daley MJ, Gebel HM, Lynch RG. Idiotype-specific transplantation resistance to MOPC 315 (Abrogation by post-immunization thymectomy). J Immunol. 1978;120:1620–1624
  12. Freedman PM, Autry JR, Tokuda S, et al.  Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. J Natl Cancer Inst. 1976;56:735–740
  13. George AJT, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in the suppression of a mouse B cell lymphoma, BCL. J Immunol. 1987;138:628–634
  14. Jorgensen T, Gaudernack G, Hannestad K. Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC-315. Scand J Immunol. 1980;11:29–35
  15. Kaminski MS, Kitamura K, Maloney DG, et al.  Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol. 1987;138:1289–1296
  16. Kwak LW, Campbell MJ, Zelenetz AD, et al.  Combined syngeneic bone marrow transplantation and immunotherapy of a murine B cell lymphoma (Active immunization with tumor-derived idiotypic immunoglobulin). Blood. 1990;76:2411–2417
  17. Sirisinha S, Eisen HN. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci USA. 1971;68:3130–3135
  18. Stevenson FK, Gordon J. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. J Immunol. 1983;130:970–973
  19. Sugai S, Palmer DW, Talal N, et al.  Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB/NZWFI mice. J Exp Med. 1974;140:1547–1558
  20. Kwak LW, Young HA, Pennington RW, et al.  Vaccination with syngeneic, lym-phoma-derived Ig idiotype combined with GM-CSF primes mice for a protective T-cell response. Proc Natl Acad Sci USA. 1996;93:10972–10977
  21. Kwak LW, Campbell MJ, Czerwinski DK, et al.  Induction of immune responses in patients with B cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1991;327:1209–1215
  22. Bendandi M, Gocke CD, Kobrin CB, et al.  Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5:1171–1177
  23. Hansen OP, Clausen NA, Drivsholm A, et al.  Phase II study of intermittent 5-drug regimen (VBMCP) versus intermittent 3-drug regimen (VMP), versus intermittent melphalan and prednisone (MP) in myelomatosis. Scand J Haematol. 1985;35:518–524
  24. Oken MM, et al.  Comparison of MP with intensive VBMCP therapy for the treatment of multiple myeloma (MM). Proc Am Soc Clin Oncol. 1984;3:270; (abstr)
  25. Pavlovsky S, Saslavsky J, Tezanos Pinto M, et al.  A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide MeCCNU, and vincristine in untreated multiple myeloma. J Clin Oncol. 1984;2:836–840
  26. Blade J, San Miguel J, Alcala A, et al.  A randomized multicentric study of comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma. Blut. 1990;60:319–322
  27. Durie BG, Dixon DO, Carter S, et al.  Improved survival duration with combination chemotherapy induction for multiple myeloma (A Southwest Oncology Group study). J Clin Oncol. 1986;4:1127–1237
  28. Kildahl-Anderson O, Bjark P, Bondevik A, et al.  Multiple myeloma in central Norway 1981–1982 (A randomized clinical trial of 5-drug combination therapy versus standard therapy). Scand J Haematol. 1986;37:243–248
  29. MacLennon ICM, et al.  In: Results of the MRC myelomatosis trials for patients entered since 1980. 1987;p. 14–16 Proceedings of the British Myeloma Workshop, Blenheim Palace, London, England, October
  30. Palva IP, et al.  Aggressive combination chemotherapy in multiple myeloma. A multicentre trial. Scand J Haematol. 1985;35:205–209
  31. Attal M, Harousseau JL, Stoppa AM, et al.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma, Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–97
  32. Vesole DH, Tricot G, Jagannath S, et al.  Autotransplants in multiple myeloma (What have we learned?). Blood. 1996;88:838–847
  33. Granena A, Gore M, Gratwohl A, et al.  Allogeneic bone marrow transplantation in multiple myeloma, European Group for Bone Marrow Transplantation. N Engl J Med. 1991;325:1267–1273
  34. Angelucci E, Baronciani D, Lucarelli G, et al.  Long-term complete remission after allogeneic bone marrow transplantation in multiple myeloma. Bone Marrow Transplant. 1991;8:307–309
  35. Bensinger WI, Buckner CD, Anasetti C, et al.  Allogeneic marrow transplantation for multiple myeloma (An analysis of risk factors on outcome). Blood. 1996;88:2787–2793
  36. Björkstrand BB, Ljungman P, Svensson H, et al.  Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma (A retrospective case-matched study from the European Group for Blood and Marrow Transplantation). Blood. 1996;88:4711–4718
  37. Mehta J, Tricot G, Jagannath S, et al.  Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?. Bone Marrow Transplant. 1998;21:887–892
  38. Tricot G, Vesole DH, Jagannath S, et al.  Graft-versus-myeloma effect (Proof of principle). Blood. 1996;87:1196–1198
  39. Gahrton G. Allogeneic bone marrow transplantation in multiple myeloma. Br J Haematol. 1996;92:251–254
  40. Hornung RL, Longo DL, Bowersox OC, et al.  Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor. J Natl Cancer Inst. 1995;87:1289–1296
  41. Kwak LW, Pennington R, Longo DL. Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype (A strategy for enhancing the specific anti-tumor effect of marrow grafts). Blood. 1996;87:3053–3060
  42. Kwak LW, Taub DD, Duffy PL, et al.  Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet. 1995;345:1016–1020
  43. Cabrera R, Diaz-Espada F, Barrios Y, et al.  Infusion of lymphocytes obtained from a donor immunized with the paraprotein idiotype as a treatment in a relapsed myeloma. Bone Marrow Transplant. 2000;25:1105–1108
  44. Lauritzsen GF, Weiss S, Dembic Z, et al.  Naı̈ve idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA. 1994;91:5700–5704
  45. Massaia M, Borrione P, Battaglio S, et al.  Idiotype vaccination in human myeloma (generation of tumor-specific immune responses after high-dose chemotherapy). Blood. 1999;94:673–683
  46. Li Y, Bendandi M, Deng Y, et al.  Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. Blood. 2000;96:2828–2833
  47. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827–838
  48. Giralt S, Estey E, Albitar M, et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy (Harnessing graft-versus-leukemia without myeloablative therapy). Blood. 1997;89:4531–4536
  49. Slavin S, Nagler A, Naparstek E, et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  50. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol. 1995;13:2431–2448
  51. Williamson LM, Wimperis JZ, Wood ME, et al.  Fludarabine treatment and transfusion-associated graft-versus-host disease. Lancet. 1996;348:472–473 (letter)
  52. Khouri IF, Keating M, Korbling M, et al.  Transplant-lite (Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies). J Clin Oncol. 1998;16:2817–2824
  53. Briones J, Pereira A, Alcorta I. Transfusion-associated graft-versus-host disease (TA GVHD) in fludarabine-treated patients (Is it time to irradiate blood component?). Br J Haematol. 1996;93:739–741
  54. Fenchel K, Bergmann L, Wijermans P, et al.  Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymphoma. 1995;18:485–492
  55. Alberts DS, Durie BG, Salmon SEA. Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. Cancer Treat Rep. 1977;61:381–388
  56. Alberts DS, Salmon SE. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma (A pilot study). Cancer Chemother Rep. 1975;59:345–350
  57. Alexanian R, Yap BS, Bodey GP. Prednisone pulse therapy for refractory myeloma. Blood. 1983;62:572–577
  58. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310:1353–1356
  59. Gockerman JP, Bartolucci AA, Nelson MO. Phase II evaluation of etoposide in refractory multiple myeloma (A Southeastern Cancer Study Group trial). Cancer Treat Rep. 1986;70:801–802
  60. McConkey DJ, Chandra J, Wright S, et al.  Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol. 1996;156:2624–2630
  61. O’Brien S, Kantarjian H, Beran M, et al.  Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993;82:1695–1700
  62. Zaja F, Rogato A, Russo D, et al.  Combined therapy with fludarabine and cyclophosphamide in relapsed/resistant patients with B-cellchronic lymphocytic leukaemia and non-Hodgkin’s lymphomas. Eur J Haematol. 1997;59:327–328 (letter)
  63. Pavletic ZS, Joshi SS, Pirruccello SJ, et al.  Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant. 1998;21:33–41
  64. Bensinger WI, Clift R, Martin P, et al.  Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies (A retrospective comparison with marrow transplantation). Blood. 1996;88:2794–2800
  65. Majolino I, Corradini P, Scime P, et al.  Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant. 1998;22:449–455
  66. Solano C, Martinez C, Brunet S. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT. Bone Marrow Transplant. 1998;22:1129–1135
  67. Storek J, Gooley T, Siadek M, et al.  Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood. 1997;90:4705–4709
  68. Brown RA, Adkins D, Khoury H, et al.  Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients (graft-versus-host disease and transplant-related mortality). J Clin Oncol. 1999;17:806–812
  69. Pavletic S, et al.  Allogeneic peripheral blood stem cell transplantation is not associated with a high risk of chronic graft-versus-host disease (cGVHD). Blood. 1998;90: (suppl 1, abstr 1883)
  70. Schmitz N, Bacigalupo A, Hasenclever D. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia (First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation). Bone Marrow Transplant. 1998;21:995–1003
  71. Schmitz N, et al.  Prognostic factors for survival after allogeneic peripheral blood progenitor cell transplantation. Blood. 1998;90: (suppl 1, abstr 565)
  72. Vigorito AC, Azevedo WM, Marques JF, et al.  A randomised, prospective com-parison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant. 1998;22:1145–1151
  73. Lum LG, Munn NA, Schanfield MS, et al.  The detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood. 1986;67:582–587
  74. Lum LG, Seigeuret MC, Storb R. The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients. J Clin Immunol. 1986;6:389–396
  75. Wimperis JZ, Brenner MK, Prentice HG, et al.  Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet. 1986;1:339–343
  76. Kato S, et al.  Studies on transfer of varicella-zoster-virus specific T cell immunity from bone marrow donor to recipient. Blood. 1990;75:806–809
  77. Kim S-B, Sivasubramanian B, Kwak LW. In vitro priming of myeloma antigen specific allogeneic donor T cells with idiotype pulsed dendritic cells. Leuk Lymphoma. 2003;44:1201–1208

PII: S0093-7754(03)00563-3

doi: 10.1053/j.seminoncol.2003.11.001

Seminars in Oncology
Volume 31, Issue 1 , Pages 37-46 , February 2004

Article Tools

* Image Usage & Resolution